CTNM - Contineum Therapeutics, Inc.

QQQ $ 631.97 $ -3.27 (-0.51 %)

DIA $ 473.00 $ -3.14 (-0.66 %)

SPY $ 681.93 $ -3.68 (-0.54 %)

TLT $ 89.71 $ 0.06 (0.06 %)

GLD $ 369.95 $ 1.15 (0.31 %)

Previous Close

$ 11.01

Open

$ 11.00

Bid

$ 10.84 x 63

Ask

$ 10.99 x 4

Day's Range

$ 10.89 - $ 10.89

52 Week Range

$ 3.35 - $ 20.24

Volume

82,429

Average Volume

Market Cap

254.32M

Beta (5Y Monthly)

$ 0.59

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-30-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	05-14-2025	03-31-2025	10-Q
4	03-06-2025	01-01-1970	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-14-2024	06-30-2024	10-Q
7	05-16-2024	03-31-2024	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Contineum Therapeutics Q3 EPS $(0.45) Beat...
10/30/2025 20:51:33

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate o...

this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

This Lululemon Analyst Is No Longer Bullis...
09/25/2025 12:56:47

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Biogen Analyst Begins Coverage On A B...
09/25/2025 12:42:57

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Leerink Partners Initiates Coverage On Con...
09/25/2025 11:21:38

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

Contineum Therapeutics Reports Topline Dat...
09/18/2025 12:10:39

12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 17:06:05

Morgan Stanley Maintains Overweight on Con...
08/18/2025 13:10:26

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Contineum Therapeutics Q2 EPS $(0.62) Miss...
08/05/2025 20:34:26

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

Contineum Therapeutics Completes PrMS And ...
06/25/2025 12:16:54

Contineum Therapeutics, Inc.

Morgan Stanley Maintains Overweight on Con...
05/19/2025 14:37:08

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

RBC Capital Reiterates Outperform on Conti...
05/15/2025 16:20:57

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Contineum Therapeutics Q1 EPS $(0.62) Miss...
05/14/2025 20:15:58

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Jones Trading Initiates Coverage On Contin...
03/13/2025 16:34:59

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...

Morgan Stanley Assumes Contineum Therapeut...
03/07/2025 17:19:55

Morgan Stanley analyst Jeffrey Hung assumes Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and maintains Pric...

Baird Maintains Outperform on Contineum Th...
03/07/2025 13:50:01

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from ...

Contineum Therapeutics Affirms Clinical De...
03/06/2025 21:12:48

Contineum Therapeutics Q4 2024 GAAP EPS $(...
03/06/2025 21:12:07

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate...

Contineum Therapeutics Initiates Patient D...
03/04/2025 21:16:37

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity- Topline data readout planned for ...